| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0e61263b84630539d1fc5281e3bd9ac4 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-404
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4045
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0043
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7028
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 |
| filingDate |
2010-06-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5a87cc85418bbe3099893576da08c95b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5cf8b1ca2b86ae60f26906ae63114fe2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2d7885d7e33bf0771bb1003469ede9f9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_518b94de0b1dc3efbe7d7d7c2765cc9d |
| publicationDate |
2012-08-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-2480197-A2 |
| titleOfInvention |
Formulations comprising triptan compounds |
| abstract |
The invention provides a pharmaceutical composition for intranasal administration comprising a salt of sumatriptan or a physiologically acceptable solvate thereof, an alkyl glycoside or saccharide alkyl ester and optionally at least one pharmaceutically acceptable excipient, wherein the said composition provides Tmax value of less than 30 minutes upon said administration. Other aspects and embodiments are contemplated and described. The invention also provides a pharmaceutical composition for intranasal administration comprising a triptan, a pharmaceutically acceptable vehicle and a mucosal permeation enhancer, wherein upon said administration said composition provides a Tmax substantially equivalent to subcutaneous administration of said triptan. Other aspects and embodiments are contemplated and described. |
| priorityDate |
2009-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |